Voyager Therapeutics Posts $15.34M Revenue, Beats EPS Loss Forecast by 15%
Voyager Therapeutics posted Q4 revenue of $15.34 million, up 144% from $6.28 million a year earlier and exceeding consensus by 58%. EPS loss of $0.46 beat the projected $0.54 loss by 15%, while a $202 million cash balance and 0.19 debt-to-equity ratio support operations through 2028.
1. Q4 Financial Performance
Voyager delivered revenue of $15.34 million in Q4, marking a 144% increase from $6.28 million a year earlier and exceeding the consensus estimate by 58%. The company posted an EPS loss of $0.46 per share, outperforming the projected $0.54 loss and representing a 15% positive surprise.
2. Balance Sheet and Liquidity
At quarter end, Voyager held $202 million in cash and equivalents, supporting operations into 2028. A debt-to-equity ratio of 0.19 and a current ratio of 7.64 underscore the company’s strong liquidity and low leverage profile.
3. Valuation Metrics and Outlook
Voyager’s valuation reflects its early-stage status with a negative P/E of -2.01, price-to-sales ratio of 5.66, and EV/sales of 4.95. The biotech remains focused on advancing tau-targeting Alzheimer’s assets and its NeuroShuttle neuro gene therapy platform toward preclinical and clinical milestones in 2026.